{
    "score": [
        0.8181818181818182
    ],
    "extracted": [
        0
    ],
    "abstract": [
        "sage therapeutics receiving somewhat positive news coverage , accern reports ."
    ],
    "id": "1140734.train",
    "article": [
        "headlines about sage therapeutics have trended somewhat positive this week , accern reports . the research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources . accern ranks coverage of public companies on a scale of -1 to 1 , with scores closest to one being the most favorable . sage therapeutics earned a news sentiment score of 0.13 on accern 's scale . accern also assigned press coverage about the biopharmaceutical company an impact score of 45.2379077169306 out of 100 , meaning that recent press coverage is somewhat unlikely to have an impact on the stock 's share price in the near future . ",
        "these are some of the news stories that may have effected accern 's scoring : a number of equities analysts have recently commented on sage shares . royal bank of canada lifted their target price on sage therapeutics from $ 137.00 to $ 280.00 and gave the stock a `` sell '' rating in a report on thursday , december 7th . they noted that the move was a valuation call . chardan capital upgraded sage therapeutics from a `` neutral '' rating to a `` buy '' rating and lifted their target price for the stock from $ 60.00 to $ 140.00 in a report on friday , november 10th . ",
        "jpmorgan chase & co. . reiterated an `` overweight '' rating and issued a $ 198.00 target price on shares of sage therapeutics in a report on friday , december 8th . leerink swann lifted their target price on sage therapeutics from $ 123.00 to $ 246.00 in a report on thursday , december 7th . finally , cowen reiterated a `` buy '' rating on shares of sage therapeutics in a report on monday , december 11th . one analyst has rated the stock with a sell rating , three have assigned a hold rating and twelve have issued a buy rating to the stock . ",
        "the company has a consensus rating of `` buy '' and an average price target of $ 171.21 . shares of sage therapeutics traded up $ 2.75 during mid-day trading on friday , hitting $ 169.46 . the company had a trading volume of 369,084 shares , compared to its average volume of 1,060,000 . sage therapeutics has a 52-week low of $ 44.55 and a 52-week high of $ 180.83 . the company has a market cap of $ 7,070.00 , a price-to-earnings ratio of -24.67 and a beta of 3.05 . sage therapeutics last issued its quarterly earnings results on thursday , november 2nd . ",
        "the biopharmaceutical company reported earnings per share for the quarter , topping the zacks ' consensus estimate of by $ 0.01 . the firm 's revenue was up . 0 % compared to the same quarter last year . research analysts anticipate that sage therapeutics will post -7.42 eps for the current year . in related news , insider albert robichaud sold 60,000 shares of the firm 's stock in a transaction that occurred on thursday , december 14th . the stock was sold at an average price of $ 159.43 , for a total transaction of $ 9,565,800.00 . ",
        "following the completion of the sale , the insider now directly owns 152,759 shares of the company 's stock , valued at approximately $ 24,354,367.37 . the sale was disclosed in a filing with the securities & exchange commission , which is available through this hyperlink . also , insider stephen kanes sold 44,000 shares of the firm 's stock in a transaction that occurred on wednesday , january 10th . the stock was sold at an average price of $ 177.18 , for a total value of $ 7,795,920.00 . following the sale , the insider now directly owns 46,348 shares of the company 's stock , valued at $ 8,211,938.64 . ",
        "the disclosure for this sale can be found here . insiders have sold a total of 314,247 shares of company stock valued at $ 50,465,110 over the last three months . 6.10 % of the stock is owned by corporate insiders . trademark violation notice : this piece of content was first reported by watch list news and is the property of of watch list news . if you are reading this piece of content on another publication , it was copied illegally and reposted in violation of us and international copyright & trademark law . the original version of this piece of content can be read at sage therapeuticssage therapeutics , inc is a clinical-stage biopharmaceutical company . ",
        "the company is engaged in developing and commercializing medicines to treat central nervous system disorders . the company 's lead product candidate , sage-547 is an intravenous formulation of allopregnanolone , a neurosteroid that acts as a synaptic and extrasynaptic modulator of the gamma-amino butyric acid-a receptor .   "
    ]
}